@prefix rdf: . @prefix ns1: . @prefix ns2: . ns1:DB00820 rdf:type ns2:Drug ; ns2:description "Tadalafil is an orally adminstered drug used to treat male erectile dysfunction (impotence). It is marketed worldwide under the brand name Cialis. It is a phosphodiesterase 5 (PDE5) inhibitor. Tadalafil's distinguishing pharmacologic feature is its longer half-life (17.5 hours) compared with Viagra and Levitra (4-5 hours). This longer half-life results in a longer duration of action and is, in part, responsible for the Cialis nickname of the \"weekend pill.\" This longer half-life also is the basis of current investigation for tadalafil's use in pulmonary arterial hypertension as a once-daily therapy. [Wikipedia]"@en ; ns2:dosage , , , , , , , ; ns2:generalReferences "# Naeije R, Huez S: Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother. 2007 Oct;8(14):2247-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17927481 # Burnett AL: Molecular Pharmacotherapeutic Targeting of PDE5 for Preservation of Penile Health. J Androl. 2007 Oct 17;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17942972 # Guazzi M, Samaja M: The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem. 2007;14(20):2181-91. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17691956"@en ; ns2:group "approved"@en , "investigational"@en ; ns2:halfLife "17.5 hours"@en ; ns2:indication "Used for the treatment of erectile dysfunction."@en ; ns2:manufacturer , , . @prefix owl: . @prefix ns4: . ns1:DB00820 owl:sameAs ns4:DB00820 . @prefix ns5: . ns1:DB00820 owl:sameAs ns5:DB00820 . @prefix dcterms: . ns1:DB00820 dcterms:title "Tadalafil"@en . @prefix adms: . @prefix ns8: . ns1:DB00820 adms:identifier ns8:Tadalafil , . @prefix ns9: . ns1:DB00820 adms:identifier ns9:DB00820 , , . @prefix ns10: . ns1:DB00820 adms:identifier ns10:CIA . @prefix ns11: . ns1:DB00820 adms:identifier ns11:D02008 , . @prefix ns12: . ns1:DB00820 adms:identifier ns12:PA10333 , ; ns2:mechanismOfAction "Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP."@en ; ns2:packager , , , , , , , , , , , ; ns2:patent , , , ; ns2:routeOfElimination "Tadalafil is excreted predominantly as metabolites, mainly in the feces (approximately 61% of the dose) and to a lesser extent in the urine (approximately 36% of the dose)."@en ; ns2:synonym "(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione"@en , "Cialis"@en , "Adcirca"@en , "Tadanafil"@en , "6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione"@en , "(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione"@en , "ICOS 351"@en ; ns2:toxicity "Oral, Rat LD50 = 2000 mg/kg, no deaths or toxicity."@en ; ns2:volumeOfDistribution "* 63 L"@en . @prefix ns13: . ns1:DB00820 ns13:hasAHFSCode ; ns2:proteinBinding "94%"@en ; ns2:synthesisReference "Ben-Zion Dolitzky, Dov Diller, \"Preparation of tadalafil intermediates.\" U.S. Patent US20060276652, issued December 07, 2006."@en . @prefix ns14: . @prefix ns15: . ns1:DB00820 ns14:hasConcept ns15:M0431130 . @prefix foaf: . ns1:DB00820 foaf:page , , ; ns2:IUPAC-Name ; ns2:InChI ; ns2:Molecular-Formula ; ns2:Molecular-Weight ; ns2:Monoisotopic-Weight ; ns2:SMILES ; ns2:Water-Solubility , ; ns2:logP , , ; ns2:logS . @prefix ns17: . ns1:DB00820 ns13:hasATCCode ns17:G04BE08 ; ns2:H-Bond-Acceptor-Count ; ns2:H-Bond-Donor-Count ; ns2:InChIKey ; ns2:Polar-Surface-Area--PSA- ; ns2:Polarizability ; ns2:Refractivity ; ns2:Rotatable-Bond-Count ; ns2:absorption "After single oral-dose administration, the maximum observed plasma concentration (Cmax) of tadalafil is achieved between 30 minutes and 6 hours (median time of 2 hours). Absolute bioavailability of tadalafil following oral dosing has not been determined."@en ; ns2:affectedOrganism "Humans and other mammals"@en ; ns2:casRegistryNumber "171596-29-5"@en ; ns2:category " "@en ; ns2:clearance "* oral cl=2.5 L/hr"@en ; ns2:containedIn , , , , ; ns2:Bioavailability ; ns2:Ghose-Filter ; ns2:MDDR-Like-Rule ; ns2:Melting-Point ; ns2:Number-of-Rings ; ns2:Physiological-Charge ; ns2:Rule-of-Five ; ns2:Traditional-IUPAC-Name ; ns2:pKa--strongest-acidic- ; ns2:pKa--strongest-basic- .